Mark P Nicol1,2, Samuel G Schumacher3, Lesley Workman4, Tobias Broger3,5, Cynthia Baard4, Margaretha Prins4, Lindy Bateman4, Elloise du Toit2, Judi van Heerden2, Rita Szekely3, Heather J Zar4, Claudia M Denkinger3,5. 1. Division of Infection and Immunity, School of Biomedical Sciences, University of Western Australia, Perth, Australia. 2. Division of Medical Microbiology and Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa. 3. Foundation for Innovative New Diagnostics, Geneva, Switzerland. 4. Department of Paediatrics and Child Health and South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town and Red Cross War Memorial Children's Hospital, Cape Town, South Africa. 5. Division of Tropical Medicine, Centre of Infectious Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Abstract
BACKGROUND: An accurate point-of-care test for tuberculosis (TB) in children remains an elusive goal. Recent evaluation of a novel point-of-care urinary lipoarabinomannan test, Fujifilm SILVAMP Tuberculosis Lipoarabinomannan (FujiLAM), in adults living with human immunodeficiency virus (HIV) showed significantly superior sensitivity than the current Alere Determine Tuberculosis Lipoarabinomannan test (AlereLAM). We therefore compared the accuracy of FujiLAM and AlereLAM in children with suspected TB. METHODS: Children hospitalized with suspected TB in Cape Town, South Africa, were enrolled (consecutive admissions plus enrichment for a group of children living with HIV and with TB), their urine was collected and biobanked, and their sputum was tested with mycobacterial culture and Xpert MTB/RIF or Xpert MTB/RIF Ultra. Biobanked urine was subsequently batch tested with FujiLAM and AlereLAM. Children were categorized as having microbiologically confirmed TB, unconfirmed TB (clinically diagnosed), or unlikely TB. RESULTS: A total of 204 children were enrolled and had valid results from both index tests, as well as sputum microbiological testing. Compared to a microbiological reference standard, the sensitivity of FujiLAM and AlereLAM was similar (42% and 50%, respectively), but lower than that of Xpert MTB/RIF of sputum (74%). The sensitivity of FujiLAM was higher in children living with HIV (60%) and malnourished children (62%). The specificity of FujiLAM was substantially higher than that of AlereLAM (92% vs 66%, respectively). The specificity of both tests was higher in children 2 years or older (FujiLAM, 96%; AlereLAM, 72%). CONCLUSIONS: The high specificity of FujiLAM suggests utility as a "rule-in" test for children with a high pretest probability of TB, including hospitalized children living with HIV or with malnutrition.
BACKGROUND: An accurate point-of-care test for tuberculosis (TB) in children remains an elusive goal. Recent evaluation of a novel point-of-care urinary lipoarabinomannan test, Fujifilm SILVAMP Tuberculosis Lipoarabinomannan (FujiLAM), in adults living with human immunodeficiency virus (HIV) showed significantly superior sensitivity than the current Alere Determine Tuberculosis Lipoarabinomannan test (AlereLAM). We therefore compared the accuracy of FujiLAM and AlereLAM in children with suspected TB. METHODS: Children hospitalized with suspected TB in Cape Town, South Africa, were enrolled (consecutive admissions plus enrichment for a group of children living with HIV and with TB), their urine was collected and biobanked, and their sputum was tested with mycobacterial culture and Xpert MTB/RIF or Xpert MTB/RIF Ultra. Biobanked urine was subsequently batch tested with FujiLAM and AlereLAM. Children were categorized as having microbiologically confirmed TB, unconfirmed TB (clinically diagnosed), or unlikely TB. RESULTS: A total of 204 children were enrolled and had valid results from both index tests, as well as sputum microbiological testing. Compared to a microbiological reference standard, the sensitivity of FujiLAM and AlereLAM was similar (42% and 50%, respectively), but lower than that of Xpert MTB/RIF of sputum (74%). The sensitivity of FujiLAM was higher in children living with HIV (60%) and malnourished children (62%). The specificity of FujiLAM was substantially higher than that of AlereLAM (92% vs 66%, respectively). The specificity of both tests was higher in children 2 years or older (FujiLAM, 96%; AlereLAM, 72%). CONCLUSIONS: The high specificity of FujiLAM suggests utility as a "rule-in" test for children with a high pretest probability of TB, including hospitalized children living with HIV or with malnutrition.
Authors: Anne K Detjen; Andrew R DiNardo; Jacinta Leyden; Karen R Steingart; Dick Menzies; Ian Schiller; Nandini Dendukuri; Anna M Mandalakas Journal: Lancet Respir Med Date: 2015-03-24 Impact factor: 30.700
Authors: Sylvia M LaCourse; Patricia B Pavlinac; Lisa M Cranmer; Irene N Njuguna; Cyrus Mugo; John Gatimu; Joshua Stern; Judd L Walson; Elizabeth Maleche-Obimbo; Julius Oyugi; Dalton Wamalwa; Grace John-Stewart Journal: AIDS Date: 2018-01-02 Impact factor: 4.177
Authors: Stephen D Lawn; Andrew D Kerkhoff; Rosie Burton; Charlotte Schutz; Andrew Boulle; Monica Vogt; Ankur Gupta-Wright; Mark P Nicol; Graeme Meintjes Journal: BMC Med Date: 2017-03-21 Impact factor: 8.775
Authors: Tobias Broger; Bianca Sossen; Elloise du Toit; Andrew D Kerkhoff; Charlotte Schutz; Elena Ivanova Reipold; Amy Ward; David A Barr; Aurélien Macé; Andre Trollip; Rosie Burton; Stefano Ongarello; Abraham Pinter; Todd L Lowary; Catharina Boehme; Mark P Nicol; Graeme Meintjes; Claudia M Denkinger Journal: Lancet Infect Dis Date: 2019-05-30 Impact factor: 25.071
Authors: Tobias Broger; Mark P Nicol; Rita Székely; Stephanie Bjerrum; Bianca Sossen; Charlotte Schutz; Japheth A Opintan; Isik S Johansen; Satoshi Mitarai; Kinuyo Chikamatsu; Andrew D Kerkhoff; Aurélien Macé; Stefano Ongarello; Graeme Meintjes; Claudia M Denkinger; Samuel G Schumacher Journal: PLoS Med Date: 2020-05-01 Impact factor: 11.069
Authors: George B Sigal; Abraham Pinter; Todd L Lowary; Masanori Kawasaki; Andra Li; Anu Mathew; Michael Tsionsky; Ruixiang Blake Zheng; Tatiana Plisova; Ke Shen; Kiyonori Katsuragi; Alok Choudhary; William J Honnen; Payam Nahid; Claudia M Denkinger; Tobias Broger Journal: J Clin Microbiol Date: 2018-11-27 Impact factor: 5.948
Authors: Ankur Gupta-Wright; Elizabeth L Corbett; Joep J van Oosterhout; Douglas Wilson; Daniel Grint; Melanie Alufandika-Moyo; Jurgens A Peters; Lingstone Chiume; Clare Flach; Stephen D Lawn; Katherine Fielding Journal: Lancet Date: 2018-07-20 Impact factor: 79.321
Authors: Stephanie Bjerrum; Tobias Broger; Rita Székely; Satoshi Mitarai; Japheth A Opintan; Ernest Kenu; Margaret Lartey; Kennedy K Addo; Kinuyo Chikamatsu; Aurélien Macé; Samuel G Schumacher; Emmanuel Moreau; Maunank Shah; Isik Somuncu Johansen; Claudia M Denkinger Journal: Open Forum Infect Dis Date: 2019-12-21 Impact factor: 3.835
Authors: Alexander W Kay; Tara Ness; Sabine E Verkuijl; Kerri Viney; Annemieke Brands; Tiziana Masini; Lucia González Fernández; Michael Eisenhut; Anne K Detjen; Anna M Mandalakas; Karen R Steingart; Yemisi Takwoingi Journal: Cochrane Database Syst Rev Date: 2022-09-06
Authors: Bryan J Vonasek; Kendra K Radtke; Paula Vaz; W Chris Buck; Chishala Chabala; Eric D McCollum; Olivier Marcy; Elizabeth Fitzgerald; Alexander Kondwani; Anthony J Garcia-Prats Journal: Expert Rev Respir Med Date: 2022-02-28 Impact factor: 4.300
Authors: Bryan Vonasek; Tara Ness; Yemisi Takwoingi; Alexander W Kay; Susanna S van Wyk; Lara Ouellette; Ben J Marais; Karen R Steingart; Anna M Mandalakas Journal: Cochrane Database Syst Rev Date: 2021-06-28
Authors: Alexander W Kay; Helena Rabie; Elizabeth Maleche-Obimbo; Moorine Penninah Sekadde; Mark F Cotton; Anna M Mandalakas Journal: Pathogens Date: 2021-12-29